Phase 1b trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas

被引：0
|
作者：
Van Tine, Brian Andrew
Chen, Christopher T.
Moreno, Victor
Davis, Elizabeth J.
de Miguel, Maria J.
Italiano, Antoine
Saada-Bouzid, Esma
Milhem, Mohammed
Valverde, Claudia
Chawla, Sant P.
Naqash, Abdul Rafeh
Carter, Louise
Jones, Robin
Conti, Ilaria
Boni, Joe
Havenith, Karin
LeBruchec, Yvan
Pantano, Serafino
Blay, Jean-Yves
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT059
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
    Somaiah, Neeta
    Conley, Anthony P.
    Parra, Edwin Roger
    Lin, Heather
    Amini, Behrang
    Soto, Luisa Solis
    Salazar, Ruth
    Barreto, Carmelia
    Chen, Honglei
    Gite, Swati
    Haymaker, Cara
    Nassif, Elise F.
    Bernatchez, Chantale
    Mitra, Akash
    Livingston, John Andrew
    Ravi, Vinod
    Araujo, Dejka M.
    Benjamin, Robert
    Patel, Shreyaskumar
    Zarzour, Maria A.
    Sabir, Sharjeel
    Lazar, Alexander J.
    Wang, Wei-Lien
    Daw, Najat C.
    Zhou, Xiao
    Roland, Christina L.
    Cooper, Zachary A.
    Rodriguez-Canales, Jaime
    Futreal, Andrew
    Soria, Jean-Charles
    Wistuba, Ignacio I.
    Hwu, Patrick
    LANCET ONCOLOGY, 2022, 23 (09): : 1156 - 1166
  • [32] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [33] Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors
    Rodriguez-Rivera, Ildefonso Ismael
    Moser, Justin C.
    Opyrchal, Mateusz
    Curti, Brendan
    Bilen, Mehmet A.
    Park, Saero
    Bruno, Marissa
    Windt, Paul
    Subramanian, Kulandayan K.
    Chopra, Sameer S.
    Isaacs, Randi
    CANCER RESEARCH, 2023, 83 (08)
  • [34] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [35] Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
    Chawla, Sant P.
    Staddon, Arthur P.
    Baker, Laurence H.
    Schuetze, Scott M.
    Tolcher, Anthony W.
    D'Amato, Gina Z.
    Blay, Jean-Yves
    Mita, Monica M.
    Sankhala, Kamalesh K.
    Berk, Lori
    Rivera, Victor M.
    Clackson, Tim
    Loewy, John W.
    Haluska, Frank G.
    Demetri, George D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (01) : 78 - 84
  • [36] A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
    Ramasamy, Karthik
    Nooka, Ajay
    Quach, Hang
    Htut, Myo
    Popat, Rakesh
    Liedtke, Michaela
    Tuchman, Sascha A.
    Laubach, Jacob
    Gasparetto, Cristina
    Chanan-Khan, Asher
    Hertzberg, Mark
    deMario, Mark
    Nueesch, Eveline
    Chesne, Evelyne
    Franjkovic, Izolda
    Lechner, Katharina
    Kornacker, Martin
    Cho, Hearn Jay
    BLOOD CANCER JOURNAL, 2021, 11 (09)
  • [37] A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
    Karthik Ramasamy
    Ajay Nooka
    Hang Quach
    Myo Htut
    Rakesh Popat
    Michaela Liedtke
    Sascha A. Tuchman
    Jacob Laubach
    Cristina Gasparetto
    Asher Chanan-Khan
    Mark Hertzberg
    Mark deMario
    Eveline Nueesch
    Evelyne Chesne
    Izolda Franjkovic
    Katharina Lechner
    Martin Kornacker
    Hearn Jay Cho
    Blood Cancer Journal, 11
  • [38] Effect of high-dose ifosfamide in advanced soft tissue sarcomas.: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    Nielsen, OS
    Judson, I
    van Hoesel, Q
    le Cesne, A
    Keizer, HJ
    Blay, JY
    van Oosterom, A
    Radford, JA
    Svancárová, L
    Krzemienlecki, K
    Hermans, C
    van Glabbeke, M
    Oosterhuis, JW
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (01) : 61 - 67
  • [39] A Phase 1b Dose-Escalation Study of Carotuximab in Combination with Nivolumab in Patients with Metastatic NSCLC
    Robert, F.
    Gray, J. E.
    Trigeiro, A.
    Adams, B.
    Theuer, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S725 - S726
  • [40] A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
    Kambhampati, Swetha
    Fakhri, Bita
    Ai, Weiyun
    Kaplan, Lawrence D.
    Tuscano, Joseph
    Wieduwilt, Matthew J.
    Sudhindra, Akshay
    Hwang, Jimmy
    Reiner, Jesika
    Martinelli, Michelle
    Aoun, Charlie
    Ta, Teresa
    Le, Diem
    Padilla, Michelle
    Crawford, Erika
    Andreadis, Charalambos
    BLOOD, 2019, 134
12345